Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D8ZK
|
|||
| Former ID |
DNCL002071
|
|||
| Drug Name |
OBP-301
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 1/2 | [1] | |
| Head and neck cancer [ICD-11: 2D42] | Phase 1/2 | [1] | ||
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1/2 | [1] | ||
| Company |
Oncolys Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.